Perspective Therapeutics’ Post

Lots of interest in this target for both diagnostic imaging and therapeutic applications.

𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗦𝗻𝗶𝗽 𝟮.𝟮𝟰: Researchers have developed porphyrin-loaded lipid #microbubbles that can effectively target and treat #cancer cells. #Porphyrins are organic compounds with imaging and #therapeutic properties. By loading them onto microbubbles, their #solubility and #bioavailability are improved. The microbubbles, when combined with #ultrasound, enhance the anticancer effects of porphyrins. The study demonstrated their effectiveness against breast cancer cells and showed their potential for #bioimaging and targeted drug therapy. Read the full paper here: https://lnkd.in/d29eRehU #IITGNResearchSnips #Research #IITGNResearchers

In case you missed it, be sure to view our feature article in the most recent edition of European Biotechnology Magazine. In the article, Indivumed Therapeutics VP of Advanced Analytics, Dr. Jonathan Woodsmith, had the chance to share updates on our work to optimize early discovery for precision therapeutics. View the full article: https://bit.ly/3Qk0Wyt #BeyondGenomics #Oncology #Cancer Research

🔥Don't miss this article from ESMO - European Society for Medical Oncology on how oligoprogression in metastatic #NSCLC could be effectively treated with SBRT plus standard-of-care ✅CURB study provides the first randomised evidence of benefit from SBRT in patients with oligoprogressive NSCLC ✅Analysis of #ctDNA from CURB study provides a valuable insight into potential utility of this technology Read here👇 https://ow.ly/4K0550QpunV #MedEd #Oncology

I'm very pleased to serve on the Clinical and Regulatory Advisory Board of AffyImmune Therapeutics - Hagop Youssoufian https://lnkd.in/dprenUyF #Cancer #Career #CARTTherapies #LungCancer #OncoDaily #Oncology #ThyroidCancer #Biotechnology

Virtual Tumour™ is a semi-mechanistic model that represents the cell cycle, DNA damage/repair and elements of the immune response. Using available PKPD data, our model predicts how different combinations of anti-cancer drugs, including radiation, impact tumour growth. Discover how our cutting-edge technology helps you speed up the development of safe & efficacious #cancer drugs 🧬📈 https://bit.ly/3vhq3Iz #MathematicalModelling #VirtualTumour #Cancer #CancerResearch #DrugDevelopment #CombinationTherapies #Oncology #ClinicalTrials #ResearchandDevelopment #BioTech #Pharma #ComputerModelling #PYC

#ICYMI, Discover how master protocols streamline clinical trial design, facilitate efficient data collection, and enable simultaneous evaluation of multiple therapies. With real-world examples and expert insights, "Accelerating Drug Development of Innovative Oncologic Agents: Master Protocols" sheds light on the latest strategies driving innovation in the oncology field. Link: https://lnkd.in/eV4p748f #Allucent #BringNewTherapiesToLight #Oncology #DrugDevelopment

Review on role of Nucleophosmin (NPM1) in DDR (DNA Damage Response) and as a drug target, and how it synergizes with all 3 of our DDR oncology targets APE1 (Base Excision Repair DDR), POL eta/POLH (Translesion Synthesis DDR) and PARP1. https://lnkd.in/gyMa9Zhh #oncology #therapeutics #structuralbiology #drugdiscovery

What matters to biotechs conducting early phase research in the realm of hematological oncology? Allucent partnered with Pharma Intelligence to conduct a survey of over 200 biotechs in the hematological oncology space to understand the challenges they have faced in their early phase research, what support they need to execute trials successfully, and what the future of these studies looks like. Download the report here: https://lnkd.in/gzCn3tJV #Allucent #BringNewTherapiesToLight #ASH23 #Hematology #Oncology